Welcome to our dedicated page for Advent Technologies Holdng SEC filings (Ticker: ADN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Advent Technologies Holdings, Inc. (ADN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents explain how Advent describes its fuel cell and hydrogen technology business, its capital structure, governance, and key risks.
Through Advent’s annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review management’s discussion of operations, financial statements, and information about its HT-PEM fuel cell systems, Membrane Electrode Assembly (MEA) technology, and related markets. When a report is delayed, notifications such as Form 12b-25 (NT 10-Q) describe the reasons for late filing and the expected timing.
Current reports on Form 8-K document material events, including equity purchase agreements and loans with Hudson Global Ventures LLC, pre-funded warrants, orders and contracts, and communications from The Nasdaq Stock Market LLC regarding listing compliance and delisting proceedings. One 8-K filed in October 2025 reports Nasdaq’s determination to commence delisting and suspend trading of Advent’s common stock and warrants, and notes the expectation that ADN and ADNWW will trade on the OTC market.
Proxy materials such as the DEF 14A detail proposals for director elections, auditor ratification, incentive plan amendments, and advisory votes on executive compensation and its frequency. Registration statements like the S-1 describe offerings of common stock, use of proceeds, risk factors, and the terms of equity purchase arrangements.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as capital-raising terms, governance changes, and listing status disclosures. Users can also review Form 4 and other insider transaction reports when available, to see how officers, directors, and significant shareholders transact in ADN securities over time.
Advent Technologies Holdings, Inc. reported Q3 2025 net income of $8.6 million, reversing a prior-year net loss of $18.5 million, mainly due to an $11.7 million gain from settling a legacy payable tied to the Danish bankruptcy estate. Core operations remained weak: Q3 revenue fell to $62 thousand from $128 thousand, with an operating loss of $2.4 million. For the first nine months of 2025, revenue was $293 thousand versus $3.5 million a year earlier, while operating loss was $8.2 million, but net income reached $1.6 million because of one-time items.
The balance sheet is highly strained. At September 30, 2025, Advent had $468 thousand in cash, total assets of $6.7 million, total liabilities of $24.5 million and a stockholders’ deficit of $17.8 million, with negative working capital of $16.0 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without near-term financing, citing overdue obligations, dependence on external funding, and uncertainty around cost-cutting and revenue growth.
Advent Technologies Holdings, Inc. filed a Form 12b-25 to notify regulators and investors that it will not file its Quarterly Report on Form 10-Q for the period ended September 30, 2025 by the normal deadline. The company states that, without unreasonable effort or expense, it needs more time to complete the final review of its financial statements and other disclosures in the report.
Advent explains that it is working diligently to finish the Quarterly Report as quickly as possible so that it can provide updated financial information for the quarter to the market.
Advent Technologies (ADN) repaid and terminated a short-term financing note. The company fully repaid a Convertible Promissory Note with an aggregate principal amount of
The original financing also included a pre-funded warrant to purchase 130,000 shares of common stock. The filing focuses on extinguishing the debt obligation; it does not alter the described warrant terms.
Advent Technologies Holdings, Inc. announced that two directors resigned from the Board. Marc Seelenfreund resigned effective October 29, 2025, and Joseph Celia resigned effective October 30, 2025. The company stated that both resignations were not due to any disagreement with the company on matters related to operations, policies, or practices.
Advent Technologies Holdings, Inc. reported it received a notice from Nasdaq that the exchange will commence proceedings to delist its common stock and public warrants for failure to comply with Nasdaq Listing Rule 5550(b)(1). Trading in both securities will be suspended effective October 30, 2025.
Nasdaq will apply to the SEC to complete the delisting process. The company’s common stock is expected to continue trading on the OTC market under the symbol ADN, and its public warrants are expected to trade on the OTC under ADNWW.
Advent Technologies Holdings (ADN) reported results from its October 22, 2025 annual meeting. Stockholders elected Class II directors Marc Seelenfreund (878,371 for) and Seth Lukash (898,871 for), and Joseph Celia (900,171 for). They ratified M&K CPAS, PLLC as auditor with 1,161,826 votes for.
Shareholders approved a Nasdaq Listing Rule 5635(d) item permitting the potential issuance and sale of 20% or more of common stock under a purchase agreement with Hudson Global Ventures, LLC, under which Hudson Global may purchase up to $52,000,000 of common stock from time to time. They also approved an amendment to the 2021 Incentive Plan, increasing shares issuable from 530,976 to 1,011,627 and adding an annual increase beginning January 1, 2027 through January 1, 2046, equal to the lesser of 3% of shares outstanding at the prior fiscal year-end or a smaller number set by the Board.
Stockholders approved the advisory say-on-pay (829,029 for) and indicated a preference on say-on-pay frequency, with 559,297 votes for every three years. As of September 19, 2025, shares outstanding were 3,291,634, and 1,307,771 shares were represented at the meeting.
ADN Definitive Proxy Statement excerpts show the company is asking shareholders to elect three Class II directors to serve until the 2028 annual meeting ("Proposal 1"). The compensation committee reviewed its philosophy and 2024 program design, elected not to establish a formal peer group and relied on survey data for benchmarking. Executives elected to forgo compensation beginning in June 2024; the deferred amounts are recorded as an accrued liability. Gary Herman (Chief Executive Officer/PEO) did not receive compensation during 2024. On October 24, 2024, Mr. Gregoriou’s termination for cause resulted in forfeiture of 36,217 vested options and 36,217 vested RSUs plus 10,601 unvested options and 10,601 unvested RSUs. Restricted stock unit market value is based on a $5.00 closing price on December 31, 2024.
Advent Technologies Holdings, Inc. filed an 8-K reporting a material transaction: the company entered into a Securities Purchase Agreement dated
Advent Technologies Holdings, Inc. received a Nasdaq delisting determination after failing to restore stockholders’ equity to the level required by Nasdaq Listing Rule 5550(b)(1), which calls for at least
The Form 10-Q filed on
Advent Technologies Holdings, Inc. (ADN) files an S-1 describing a fuel-cell technology business built by experienced electrochemists and led by Dr. Emory De Castro. The company focuses on a high-temperature PEM membrane-electrode assembly (MEA) targeting 160-180°C operation and durability beyond 20,000 hours and lists marine, aviation and human portable power as end markets. As of June 30, 2025 the company had $0.1 million cash and 2,670,286 shares outstanding and reports no revenue recognized in the three- and six-month periods ending June 30, 2025. The filing discloses multiple short-term high-interest loans refinanced in 2025 with effective annual rates stated as ~292.82%, 250.67% and 206%. The company holds numerous warrants exercisable at $345.00 per share and notes material going-concern and covenant risks, overdue obligations, and the need for immediate additional funding to continue operations.
FAQ
What is the current stock price of Advent Technologies Holdng (ADN)?
What is the market cap of Advent Technologies Holdng (ADN)?
